News

Despite an FDA CRL over usability, trial data suggest the needle-free epinephrine film rivals autoinjectors in speed and absorption, with promise for real-world readiness.

Hovanesian breaks down the process by which Yuvezzi received FDA approval and discusses the prescription and application of the new drug.

The 2025 KDIGO guidelines guide mechanism-driven therapy in IgA nephropathy, highlighting targeted interventions across the 4-hit disease cascade.

Catch up on dermatology news from January 2026, expert insights on dermatologic disease management, and more.

This segment of Liszewski’s interview at Maui Derm Hawaii 2026 highlights additional takeaways for clinicians regarding the treatment of contact dermatitis.

New data presented at EHSF in Malta boasts a reduced proportion of patients with severe HS at 3 years.

Tegoprubart, a CD40L-targeted therapy, may improve long-term kidney transplant outcomes by reducing immune-mediated injury.

The DROP-FPF Phase 3b trial will use automated HRCT biomarkers to assess whether early treatment with nerandomilast can slow disease progression before lung function declines.

Russman highlights asundexian’s efficacy in patients following a non-cardioembolic ischemic stroke or high-risk transient ischemic attack.

Vaginal delivery, exclusive breastfeeding, and early sibling exposure strongly predicted colonization with bifidobacteria that suppress IgE responses in a recent study.

New study shows baseline impulsivity links to residual symptoms but not relapse, highlighting the need for individualized, clinician-guided decisions.

In the final segment, experts discuss how to navigate traditional or cultural foods with patients in the absence of their inclusion in the guidelines.

In part 7 of the discussion, experts reflect on access issues regarding foods recommended in the guidelines.

Part 6 of the discussion takes a closer look at added sugar recommendations from the guidelines and scenarios where individualization may be needed.

In part 5 of the discussion, the panel examines gaps within the pediatric sections of the updated dietary guidelines.

In part 4 of the discussion, experts review notable omissions and oversights in the guidelines, including fiber, whole grains, and plant-based foods.

In part 3 of this discussion, experts break down saturated fat recommendations and why visuals in the guidelines may cause confusion.

In part 2 of the discussion, experts discuss recommendations around protein intake, including controversy and misconceptions.

In the opening segment of this special report, a trio of experts discuss what's new in the 2025-2030 Dietary Guidelines.

This secondary analysis of the phase 3b SOUL cardiovascular outcomes trial indicates oral semaglutide’s potential capacity to reduce HF events.

Reau and Brown are joined by Amanda Van Jacobs, MS, RDN, and Jessica Mellinger, MD, to discuss the new dietary guidelines through the lens of liver health.

Delay discounting links to residual depression symptoms but does not predict relapse after stopping antidepressant treatment in patients with remitted MDD.

In this Maui Derm Hawaii 2026 interview, key takeaways on contact dermatitis treatment strategies are highlighted by Liszewski.

Catch up on hepatic FDA news, expert insights on PBC and MASH developments, & more.

Longitudinal data identify aromatic lactate–producing bifidobacteria and the metabolite 4-hydroxy-phenyllactate as key factors in early immune tolerance.

January 2026 Hematology Month in Review highlights new ASH and KDIGO guidelines, FDA approvals, and pipeline progress in rare blood disorders.

FDA approvals, priority review decisions, and new data on treatment response and mechanisms highlight a month of progress in MDD and ADHD.

This interview at Maui Derm 2026 highlights notable takeaways regarding psoriasis treatment strategies and emerging therapies.